Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Moxifloxacin Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Harrow Launches VIGAMOX in the U.S.
Details : VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) is a fluoroquinolone antibiotic eye drop approved for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms.
Product Name : Vigamox
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 31, 2023
Lead Product(s) : Moxifloxacin Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Moxifloxacin Hydrochloride
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : Ophthalmology Associates, St Louis | Bausch & Lomb Incorporated
Deal Size : Inapplicable
Deal Type : Inapplicable
2-Site Safety Study of Besivance Versus Vigamox Prophylactically in Routine Cataract Surgery
Details : Vigamox is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 19, 2011
Lead Product(s) : Moxifloxacin Hydrochloride
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : Ophthalmology Associates, St Louis | Bausch & Lomb Incorporated
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Moxifloxacin Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AL-15469A is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Conjunctivitis, Bacterial.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 11, 2010
Lead Product(s) : Moxifloxacin Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable